Biosynthesis of Anisotropic Silver Nanoparticles by Bhargavaea indica and Their Synergistic Effect with Antibiotics against Pathogenic Microorganisms

Figure 6

Zones of inhibition of partially purified silver nanoparticles pellet solution 30 μL (100 ppm) and standard antibiotics as control, against Salmonella enterica, Escherichia coli, Vibrio parahaemolyticus, Bacillus anthracis, Bacillus cereus, and Staphylococcus aureus, respectively (a). Zones of inhibition of standard antibiotics disks with anisotropic silver nanoparticles against Salmonella enterica, Escherichia coli, Vibrio parahaemolyticus, Bacillus anthracis, Bacillus cereus, Staphylococcus aureus, and Candida albicans (b), respectively. Note. (1) Lincomycin (MY15) 15 µg/disk, (2) oleandomycin (OL15) 15 µg/disk, (3) novobiocin (NV30) 30 µg/disk, (4) vancomycin (VA30) 30 µg/disk, (5) penicillin G (P10) 10 µg/disk, and (6) rifampicin (RD5) 5 µg/disk; cycloheximide (CHX) 10 µg/disk and anisotropic silver nanoparticles (AgNPs) 30 µL (100 ppm).

(a)

(b)